SIBP-A13

N/A

Report date: 2024/02/05 14:05:20

Base Information

Drug NameSIBP-A13
Drug Alias NameSIBP-A13
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionReceptor tyrosine-protein kinase erbB-3 antagonists
TargetsReceptor tyrosine-protein kinase erbB-3
Therapy Area/IndicationsMetastatic breast cancerSolid tumoursCarcinoma, Non-Small-Cell Lung +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesShanghai Institute of Biological Products Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesShanghai Institute of Biological Products Co Ltd
Inactive CompaniesN/A
Active IndicationsMetastatic breast cancerSolid tumoursCarcinoma, Non-Small-Cell Lung +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A